• Trials and Research

  Potential B-cell Targeting MS Therapy, PRN2246, Seen to Reach Brain in Phase 1 Study

  Posted by MS News Today Moderator on August 7, 2018 at 8:13 am

  Principia Biopharma releases Phase 1 data on PRN2246, confirming the oral agent can cross the blood-brain barrier to target B-cells that drive inflammation.

  Read more about this study here: Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study.

  What do you think about this news?

  replied 5 years, 8 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply